Monitor upcoming earnings and pipeline updates closely, coordinated C-suite selling, especially by the CEO, often precedes downward revisions or clinical setbacks. Consider this a warning sign despite recent analyst optimism.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 15 $40.95entry
- T+1 · 7mo ago −3.44%α −3.70% · $39.54
- T+5 · 7mo ago −2.10%α −3.74% · $40.09
- T+20 · 6mo ago +4.62%α −1.43% · $42.84
- T+60 · 4mo ago +38.19%α +30.06% · $56.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Five executives at Travere Therapeutics, including the CEO, CFO, and CMO, sold shares in a coordinated cluster totaling $2.99M over a 7-day period, with the CEO accounting for $2.33M of the total. This represents a significant insider selling event involving key C-suite leaders, suggesting potential lack of confidence in near-term prospects despite no disclosed fundamental changes.
Key Financial Metrics
Key Facts
- Five insiders sold a total of $2.99M in shares over 7 days
- CEO Dube Eric M. sold 56.8K shares for $2.33M, representing 78% of total cluster value
- All transactions were open-market sales (code S), not related to grants or tax events
- Sales occurred at prices between $39.09 and $42.61 per share
- Total cluster value represents ~0.08% of $3.7B market cap, modest in relative terms but highly concentrated among top executives
Financial Impact
$2.99 million in insider selling over 7 days, with $2.33M from the CEO alone
Risk Factors
- Potential for negative clinical or regulatory news in the near term
- Erosion of investor confidence due to concentrated executive selling
- Possible misalignment between management and shareholder interests
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TVTX-1776974730257 |
Track record
21 reports on TVTX
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers